Rs. 8200 Crore Group Dealing in Pharmaceuticals and Power Based in Ahmedabad

 Rs.
8200 crore Group
 Dealing in Pharmaceuticals
and Power
 Based in Ahmedabad.
The Founder
Shri U N Mehta
“It is pardonable to aim high and miss,

but it is not pardonable to aim low”
Promoters
Shri Sudhir U Mehta - Chairman,

 Shri Samir Mehta –
[Torrent Group] Vice Chairman
 Joined the family business in the early 70s,  A trained businessman

extending his firm support during the setting- with a youthful and exuberant
up of the business. attitude contributing immensely
to the organization’s functioning.
 His dynamism and business acumen
reinforced with his father’s experience
resulted into the initial success of Torrent
Pharma.
The Genesis
 Shri U.N. Mehta pioneered the concept of ‘niche marketing’ in the Indian
Pharma industry almost four decades ago.
 Starting with anti-rheumatic drugs, Shri U.N. Mehta discovered largely

untapped territory in marketing medicines to specific segments. This was ‘niche
marketing’ in its earliest form, a radical departure from the usual practice of
those times and Shri Mehta’s great contribution to the Indian pharmaceutical
industry.
 In the mid-90s, with steady and increasing returns from its Pharma
business, the Company diversified into Power sector.
 acquisition of two of the country’s oldest utilities, The Ahmedabad Electricity

Company Ltd. and The Surat Electricity Company Ltd., in the 90s
Buisness Areas
 Pharmaceuticals Sector
 Power Sector
Group Structure
Group Companies
 Torrent Pvt Ltd.

– apex company of the Torrent Group.
– Synergizing the group activities, it monitors and manages the group’s
investments and promotes the corporate image of Torrent.
 Torrent Pharmaceuticals Ltd.
– Flagship Company
– Annual Turnover of Rs 1900 Crores
– Sixth largest company in the Indian pharmaceuticals
– 1000 product registrations and exports to more than 50 countries
 Torrent Power Ltd.
– Generating capacity of 1647.5 MW
 Torrent Cables Ltd.
– 1989-90 :: Mahendra Electricals taken over and renamed as
‘Torrent Cables Ltd.' - Torrent’s initial foray into power
CMIE Classification
 Torrent Pharmaceuticals Ltd.

– All Industries
 Non Financial
– Chemicals
 Drugs and Pharmaceuticals
MANUFACTURING
PLANTS
 Indrad Plant
– Set up in 1989
– Complies with WHO, cGMP, MHRA and TGA
norms
– Has received ISO 9001, ISO 14001 and OHSAS
18001
 Baddi Plant
– Set up in Nov 2005
– Caters to Domestic Market
Indrad Plant
 Infrastructure
– Land - 178,000 sq. metres
– Built-up Area - 50,000 sq. metres for Formulations, 10,000 sq.
meters for API
– Finished Products - Oral Dosage Form, Injectables, Freeze Dried
Sterile Injections
– API - Multi Product, Versatile Facility, Upgraded to International
Standards
– Hygiene Zones – Process step dependent special zones created
for each type of activity
Indrad Plant
 Manufacturing Capacities (per annum) ::

– Formulations - Tablets, capsules and vials 6,000 million
– Bulk Drugs/API 15,000 kg
Indrad Plant
 Tie-up with Novo Nordisk ::

 An agreement with Novo Nordisk India in August
2005.
– Part of facility is dedicated for the formulation and
packaging of Insulin, exclusively for Novo Nordisk.
– Won the award for Best Maintained Manufacturing Site of
Novo Nordisk worldwide.
Indrad Plant
 Facilities
– Tablet Facility
– Capsule Facility
– Packaging Facility
– Quality Control Facility
– Active Pharmaceutical Ingredients Plant Facility
– Supply Chain Management Facility
– Engineering Services Facility
– New Facilities
Capsule Facility
 ENCAPSULATION
 Hard Gelatin
– Pellet Filling
– Tablet Filling
– Combination of Powder/Pellet & Powder / Tablet Filling
 Soft Gelatin
Tablet Facility
 Tablet facility: Modernized / Upgraded to Meet International Standards.
 Department has following Hygiene Zones:
– 'O' Area - Products exposed to environment
– 'E' Area - Products in close containers
– Entry from 'E' to 'O' area is restricted by separate gowning procedure.
 Area-wise personnel and material movement through separate air lock.
 All manufacturing area has 100% fresh air to avoid cross contamination.
 Equipments ::
– Wet Granulation
– Dry Compaction / Granulation
– Pellet Coating
– Film Coating
– Enteric Coating
– Sugar Coating
– Bilayer Tablet
Parentals Facility
 Facility has been designed under technical guidance

of M/s. Novo Nordisk, Denmark which complies
International Regulations.
– VIAL : INSULIN
– AMPOULE
– FREEZE DRYING
PACKAGING
Aluminium - PVC / PVDC (Blister)

Aluminium - Aluminium Foil (Strips)
Aluminium - Aluminium (Cold forming)
Bulk Packaging
Pouch Packaging (triple laminated foil)
Vials / Bottle Packging
Baddi Plant
 Set up with an investment of over Rs. 130 crores, the

Baddi Plant is a most modern, state-of-the-art facility
 Caters to the requirements of domestic markets.
 The Plant commenced operations in November 2005
 Capacity to manufacture 3600 million tablets, 400 million
capsules and 18 million Oral Liquid bottles, per annum.
 Production of most of the domestic products shifted to
Baddi.
Baddi Plant
 Infrastructure :
– Land – 82, 237 sq. metres
– Built-up Area – 23, 000 sq. metres
 Plant approved by ISO/IEC 17025 in May 2006
 Recently received EU approval.
 The Chemical and Biological testing Labs have been accredited by
NABL and
 The QC Lab attested by NABL to be in accordance with the
international standards.
QUALITY CONTROL
The QC department performs following activities:

 RM/PM analysis (Flowchart)
 Finished Products analysis (Flowchart)
 In-process Checks (Flowchart)
 Stability Studies
The QC activities are managed through four sections:

Instrumental Analysis and Finished Products
Wet Analysis Laboratory
Microbiological Testing Laboratory
Packaging Material -Testing Laboratory
Flow Chart - RM / PM Inspection
Flow Chart - Inprocess Checks
Flow Chart - Finished Products
Inspections
RESEARCH
AND
DEVELOPEMENT
R&D Centre
 A team of over 600 scientists

 Offer dedicated services in the areas of Discovery Research,
Generic Drug Development and New Drug Delivery
Systems/Value Added Generics.
 Set up at an investment of over US $ 40 million
 Conforms to international quality standards and houses
advanced and up to date equipment.
 It has one of the most advanced infrastructures for both basic
and applied research.
The Establishment
 Total land area: 125,000 sq mts

 Built-up area: 38,000 Sq mts
– Laboratories: 24,000 Sq mts
– Support services: 14,000 Sq mts
 Investment: US $ 40 million
 Unique Architectural Feature
– Specially designed with passive downdraft
evaporative cooling which saves the air-conditioning
plant capacity by about 150 T.R.
Discovery Research
 Committed to innovation by discovering novel molecules and

formulating unique therapeutic approaches.
 Team of 130 highly motivated and trained scientists evenly distributed
between Chemistry and Biology.
 The focus is on understanding the pathophysiology of the target
disease and finding ways to modulate the disease process.
 Housed in the same campus as the Generic Development team
ensure seamless integration of the discovery team’s efforts into the
drug development process(ensure smooth transition from bench to the
clinic).
 Presently working on 6 discovery projects in the areas of diabetes,
metabolic syndrome, renal disease, neuropathic pain and
cardiovascular disorders.
Drug Development
 Portfolio of more than 75 products for various

markets
 The development team has vertically
integrated operations for greater control:
patent navigation, process development,
scaling-up, tech transfer and finished
formulations, registrations.
New Drug Delivery Systems/Value
Added Generics
 Capable of developing new dosage forms by

leveraging our proprietary technologies such as
Dual Retard Inlay Technology, Compact Tablet
Technology, Gastro Retentive System and Matrix
Based SR/ Modified Release Formulations.
 Some of novel (first time in the world) solutions
include Lamotrigine dispersible-OD formulation
and Nicorandil OD.
Global Certifications
ANVISA (Agencia Nacional de Vigilancia OECD - Research Certification

Sanitaria) in May 2003 Since Aug 2000
Global Certifications
NABL - Research Certification National GLP Certification

Conclusion
 Over the years, Torrent has remained focused on pharma and

power, two crucial sectors without which modern life is
unimaginable.
 Today, it is deservedly known as ‘India’s leading producer of

life supporting drugs with a significant presence in the power
sector’.

Rs. 8200 Crore Group Dealing in Pharmaceuticals and Power Based in Ahmedabad

Uploaded by

Copyright:

Available Formats

Rs. 8200 Crore Group Dealing in Pharmaceuticals and Power Based in Ahmedabad

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Rs. 8200 Crore Group Dealing in Pharmaceuticals and Power Based in Ahmedabad

Uploaded by

Copyright:

Available Formats

 Rs.

8200 crore Group

“It is pardonable to aim high and miss,

Shri Sudhir U Mehta - Chairman,

 Joined the family business in the early 70s,  A trained businessman

 Starting with anti-rheumatic drugs, Shri U.N. Mehta discovered largely

 acquisition of two of the country’s oldest utilities, The Ahmedabad Electricity

 Torrent Pvt Ltd.

 Torrent Pharmaceuticals Ltd.

 Manufacturing Capacities (per annum) ::

 Tie-up with Novo Nordisk ::

 Facility has been designed under technical guidance

Aluminium - PVC / PVDC (Blister)

 Set up with an investment of over Rs. 130 crores, the

The QC department performs following activities:

The QC activities are managed through four sections:

 A team of over 600 scientists

 Total land area: 125,000 sq mts

 Committed to innovation by discovering novel molecules and

 Portfolio of more than 75 products for various

 Capable of developing new dosage forms by

ANVISA (Agencia Nacional de Vigilancia OECD - Research Certification

NABL - Research Certification National GLP Certification

 Over the years, Torrent has remained focused on pharma and

 Today, it is deservedly known as ‘India’s leading producer of

You might also like